Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average Price Target from Brokerages

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $31.00.

A number of equities research analysts have recently commented on the stock. Weiss Ratings started coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Stifel Nicolaus began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $28.00 price target on the stock. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Morgan Stanley began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “overweight” rating and a $34.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th.

Insiders Place Their Bets

In related news, Director Robert C. Malenka sold 21,262 shares of the company’s stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $18.55, for a total value of $394,410.10. Following the completion of the transaction, the director owned 371,885 shares of the company’s stock, valued at approximately $6,898,466.75. This represents a 5.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 41,438 shares of company stock valued at $762,687.

Institutional Trading of Maplight Therapeutics

A hedge fund recently bought a new stake in Maplight Therapeutics stock. Strs Ohio bought a new position in shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 3,000 shares of the company’s stock, valued at approximately $53,000.

Maplight Therapeutics Trading Up 8.2%

Shares of MPLT stock opened at $16.98 on Thursday. Maplight Therapeutics has a 52-week low of $12.24 and a 52-week high of $21.55. The firm has a market cap of $770.43 million and a PE ratio of -0.46. The company has a 50-day moving average of $18.00.

Maplight Therapeutics (NASDAQ:MPLT) last posted its earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.